The CORA™ system goes beyond plasma and platelets to measure all phases of hemostasis in whole blood. As a result, doctors will be able to identify hemorrhagic or thrombotic tendencies in just minutes. Portable, easy-to-use CORA technology will allow personalized anticoagulation and antiplatelet therapy, which should decrease the need for blood products and may aid in reducing the risk of heart attack and stroke for a wide range of patients.
May 23, 2011
Nearly $3 million over three years will help make next-generation hemostasis monitoring a reality